New shot could tame inherited high cholesterol

NCT ID NCT07450378

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase III trial tests QLC7401, a new RNA-based drug, in 120 adults with heterozygous familial hypercholesterolemia (a genetic condition causing very high cholesterol). Participants already on cholesterol medication will receive either QLC7401 or a placebo injection. The study measures how much LDL ('bad') cholesterol drops and checks for side effects. If successful, it could offer a new way to control cholesterol in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLC7401 (a small interfering RNA drug that targets PCSK9 to lower cholesterol)
What this could lead to: If it works, this could provide a new, convenient injection option to help control very high cholesterol in people with familial hypercholesterolemia.
What could go wrong: This is a Phase III trial, but results are not yet available. The drug may not lower cholesterol enough or could cause side effects. It is tested only in people already on other cholesterol medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

More trials for these conditions

Other studies related to the condition(s) this trial covers.